Eli Lilly & Co. (LLY) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,199.43 --0%
EPS Growth %: +39.8%
Financial Fact:
Marketing, selling, and administrative: 1.57B
Today's EPS Names:
FOMI, FLES, IMMR, More
EPS Growth %: +39.8%
Financial Fact:
Marketing, selling, and administrative: 1.57B
Today's EPS Names:
FOMI, FLES, IMMR, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.94, $0.02 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $6.77 billion versus the consensus estimate of $6.6 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2021 EPS of $7.95-$8.05, versus the consensus of $6.80.
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
- Innovent and Lilly strike China deal for breast cancer drug
- UBS Upgrades Hyundai Glovis Co Ltd (086280:KS) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
